<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00674271</url>
  </required_header>
  <id_info>
    <org_study_id>20080059</org_study_id>
    <nct_id>NCT00674271</nct_id>
  </id_info>
  <brief_title>Immune Profile and Complication Risk in Type 2 Diabetes</brief_title>
  <acronym>IMPACT</acronym>
  <official_title>Immune Profile and Complications Risk in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the relation between individual differences in&#xD;
      pattern recognition molecules (PRM's) in the innate immune system and the prevalence and&#xD;
      development of vascular complications in patients with type 2 diabetes.&#xD;
&#xD;
      This is based on the hypothesis that pattern recognition molecules (PRM's) in the innate&#xD;
      immune system contributes to a chronic low grade inflammation in diabetic patients. Variation&#xD;
      in PRM's - at the genome, proteome as well as the functional level - are therefore associated&#xD;
      with the degree of chronic low grade inflammation, and probably also with the prevalence of&#xD;
      vascular complications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim: The primary aims of the project are:&#xD;
&#xD;
        1. By use of advanced magnetic resonance imaging to characterize the prevalence of&#xD;
           atherosclerosis in the carotid arteries in patients with newly diagnosed type 2&#xD;
           diabetes.&#xD;
&#xD;
        2. To investigate if individual differences in the innate immune system contributes to the&#xD;
           prevalence and development of cardiovascular disease in patients with type 2 diabetes.&#xD;
&#xD;
        3. To prospectively observe the cardiovascular morbidity and mortality in a cohort of&#xD;
           patients with type 2 diabetes seen in the light of the obtained baseline&#xD;
           characteristics.&#xD;
&#xD;
      Background: Type 2 diabetes is a very common disease in the western world. Patients with type&#xD;
      2 diabetes are at risk of a number of complications, including macroangiopathy which involves&#xD;
      an accelerated atherosclerosis, that causes most of the increased mortality and morbidity in&#xD;
      type 2 diabetics. Mounting evidence suggests that development of vascular complications is&#xD;
      associated to a chronic low grad inflammation in type 2 diabetes. Individual differences in&#xD;
      the innate immune system might contribute to this chronic low grade inflammation as it has&#xD;
      become apparent that in some situations - as after tissue ischemia or in diabetes - a change&#xD;
      in the body's own cell glycosylations occurs, which leads to increased affinity of PRM's.&#xD;
      This study will focus primarily on two families of PRM's: Collectins and Toll-like receptors.&#xD;
&#xD;
      Methods: The study consists of a prospective observational cohort study of 100 newly&#xD;
      diagnosed type 2 diabetic patients with continuous 2-year clinical follow-up and a&#xD;
      register-based follow-up of morbidity and mortality study after 5 and 10 years. Furthermore&#xD;
      100 healthy control subjects will be included. Baseline data will represent a independent&#xD;
      cross-sectional study of the relationship between the innate immune system, glycemic control&#xD;
      and the presence of atherosclerosis in the carotid arteries in newly diagnosed type 2&#xD;
      diabetic patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2008</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Plaque burden in carotid arteries</measure>
    <time_frame>Individual</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum levels of pattern recognition molecules</measure>
    <time_frame>Individual</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotyping genes for pattern recognition molecules</measure>
    <time_frame>Individual</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Diabetics</arm_group_label>
    <description>100 patients with newly diagnosed (&lt;5 years since diagnosis) type 2 diabetes referred from general practitioners to Medical Department M, Aarhus University Hospital, Denmark.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>100 healthy (no diabetes or prediabetes in oral glucose tolerance test) control subjects matched for age and gender</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        100 patients with newly diagnosed (&lt;5 years since diagnosis) type 2 diabetes referred from&#xD;
        general practitioners to Medical Department M, Aarhus University Hospital, Denmark.&#xD;
&#xD;
        100 healthy (no diabetes or prediabetes in oral glucose tolerance test) control subjects&#xD;
        matched for age and gender.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diabetics: Newly diagnosed (&lt;5 years since diagnoses) type 2 diabetes due to national&#xD;
             diagnosis criteria&#xD;
&#xD;
          -  Controls: No diabetes or prediabetes in oral glucose tolerance test&#xD;
&#xD;
        Both:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Both:&#xD;
&#xD;
          -  Pacemaker or other magnetic materials in the body&#xD;
&#xD;
          -  Severe claustrophobia&#xD;
&#xD;
          -  Pregnancy/lactation&#xD;
&#xD;
          -  Cancer - former or current&#xD;
&#xD;
          -  Acute or chronic infection&#xD;
&#xD;
          -  Dialysis-dependent kidney disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens S Christiansen, Prof., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Department M, Aarhus University Hospital, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Department M, Aarhus University Hospital</name>
      <address>
        <city>Aarhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>May 5, 2008</study_first_submitted>
  <study_first_submitted_qc>May 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2008</study_first_posted>
  <last_update_submitted>November 3, 2011</last_update_submitted>
  <last_update_submitted_qc>November 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <keyword>Mannose-Binding lectin</keyword>
  <keyword>Toll-Like Receptors</keyword>
  <keyword>Atherosclerosis</keyword>
  <keyword>Carotid Arteries</keyword>
  <keyword>Diabetes Complications</keyword>
  <keyword>Diabetic Angiopathies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

